



Inflammation Amplified: The Impact of Obesity on Psoriasis Pathophysiology and Care

Saturday, **26 September 2026**

From 13:30 to 14:30 CEST




LIVE VIRTUAL WEBINAR



For registration
CLICK HERE

REGISTRATION IS FREE OF CHARGE



OVERVIEW

This educational project explores the complex bidirectional relationship between psoriasis and overweight or obesity, highlighting the shared immune-mediated and metabolic pathways that contribute to increased disease burden and poorer clinical outcomes. The programme will support healthcare professionals in recognizing how excess weight can influence psoriasis severity, treatment response, persistence, and overall patient wellbeing.

Through practical, clinically focused content, participants will strengthen their ability to identify patients who may benefit from additional metabolic assessment, conduct respectful and effective weight-related conversations, and integrate obesity management into routine psoriasis care. The project will also provide guidance on moving from recognition to action by establishing appropriate referral pathways and promoting multidisciplinary collaboration among dermatology, primary care, obesity medicine, nutrition, and other relevant specialties.

LEARNING OBJECTIVES

- Identify shared immune-mediated pathways to improve screening and diagnosis
- Apply effective strategies to guide weight-related discussions with patients with psoriasis and comorbid obesity or overweight
- Incorporate referral pathways and multidisciplinary care

TARGET AUDIENCE

This educational program is addressed to dermatologists treating patients with psoriatic disease and overweight/obesity

LANGUAGE


English



CONTINUING MEDICAL EDUCATION

“The Inflammation Amplified: The Impact of Obesity on Psoriasis Pathophysiology and Care, Rome, Italy, Italy 26/09/2026 - 26/09/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1.0 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.” Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>





CME PROVIDER

Scientific Seminars International Foundation

Programme Manager: **Donata Richichi**

donata.richichi@scientificseminars.com - education@scientificseminars.com

MEDICAL ADVISOR

Paolo Amerio

Dermatology Clinic

Gabriele d'Annunzio University

Chieti, Italy

CHAIRMAN

Hervé Bachelez

Hôpital Saint-Louis

Imagine Institute for Human Genetic Diseases

Paris Cité University

Paris, France

FACULTY

Paolo Amerio

Dermatology Clinic

Gabriele d'Annunzio University

Chieti, Ita

Hervé Bachelez

Hôpital Saint-Louis

Imagine Institute for Human Genetic Diseases

Paris Cité University

Paris, France

Lluís Puig Sanz

Department of Dermatology Hospital de la Santa Creu i Sant Pau

Universitat Autònoma de Barcelona School of Medicine

Barcelona, Spain

Rachel Sommer

University Medical Center Hamburg – Eppendorf

Hamburg, Germany

INFLAMMATION AMPLIFIED: THE IMPACT OF OBESITY ON PSORIASIS PATHOPHYSIOLOGY AND CARE

SATURDAY, 26 SEPTEMBER 2026

From 13:30 to 14:30 CEST

Chair:		H. Bachelez (France)
13.30		Welcome and introduction H. Bachelez (France)
13.32		L1 The Psoriasis and Overweight/Obesity Connection H. Bachelez (France)
13.47		L2 Obesity's Impact on Psoriasis Treatment Outcomes P. Amerio (Italy)
13.57		L3 Communication Skills and Weight Conversations R. Sommer (Germany)
14.12		L4 From Recognition to Referral L. Puig Sanz (Spain)
14.22		Q & A General Interactive Discussion with participants Moderator: H. Bachelez (France)
14.30		Closing remarks and end of the live webinar H. Bachelez (France)


LEGEND



Lecture



Q&A General discussion with participants



FACULTY DISCLOSURES

Scientific Seminars International Foundation is committed to providing independent, balanced, evidence-based education in accordance with the standards of the European Accreditation Council for Continuing Medical Education (EACCME®).

All faculty have disclosed any relevant financial relationships with ineligible companies. These disclosures have been reviewed and, where appropriate, any potential conflicts have been mitigated to ensure the independence and scientific integrity of this activity. Presentations may include discussion of investigational or off-label uses of healthcare products. Faculty will identify such content where applicable. The views expressed are those of the individual presenters and do not necessarily reflect those of Scientific Seminars International Foundation.

The following faculty have disclosed relevant financial relationships and/or indicated that their presentation includes discussion of investigational or off-label use of healthcare products:

Paolo Amerio

Declared receipt of honoraria or consultation fees from Abbvie, J&J, Pfizer, Galderma, Eli Lilly, Sanofi, AMGEN, Novartis, Almirall, and declared participation in the Abbvie, J&J, Pfizer, Galderma, Eli Lilly, Sanofi, AMGEN, Novartis, Almirall company sponsored speaker's bureau

Hervé Bachelez

Declared receipt of grants/research support from Bristol Myers Squibb, Lilly and receipt of honoraria or consultation fees from Lilly, Bristol Myers Squibb, Janssen, Novartis, AnaptysBio. He declared Stock shareholder of Innate Pharma, Nanobiotix

Lluís Puig Sanz

Declared receipt of grants/research supports from Abbvie, Almirall, Amgen, Leo-Pharma, Lilly, Oruka, Sun Pharma, UCB and receipt of honoraria or consultation fees from Abbvie, Almirall, Amgen, Apogee, Boehringer Ingelheim, Bristol-Myers-Squibb, Horizon (DSMB), J&J Innovative Medicine, Leo. He declared participation in Bristol-Myers-Squibb, J&J Innovative Medicine, Lilly, Novartis, and UCB company sponsored speaker's bureau as well as travel support from: Almirall, Incyte, Johnson&Johnson, Lilly, UCB

Rachel Sommer

Declared receipt of grants/research support from Almirall, Beiersdorf, Incyte and receipt of honoraria or consultation fees from Abbvie, Almirall, Amgen, Apocare, Beiersdorf, Celltrion, Incyte, Jansse-Cilag, Leo Pharma, Novartis, UCB, Eli Lilly



CHAIRMAN & FACULTY

HERVÉ BACHELEZ

Professor Hervé Bachelez is Professor of Dermatology at the University Paris Cité and in the Department of Dermatology of the Saint-Louis Hospital in Paris, France. Since 2004, Professor Bachelez has been full professor of clinical dermatology at the Université Paris-Diderot/Université Paris Cité, where he received his Ph.D. in Immunology in 1999. In 2024, Professor Bachelez has also been appointed Guest Professor at Xiangya Hospital, Central South University in Changsha, China. Professor Bachelez's clinical and research activities focus on inflammatory skin diseases, mainly psoriasis and psoriasis-related diseases, but also hidradenitis suppurativa, lichen planus among others. He is conducting his basic and translational research at the Institut National de la Santé et de la Recherche Médicale (INSERM U1163), in the Laboratory of Genetics of Skin Diseases at the Imagine Institute for Human Genetic Diseases in Necker Hospital, Paris. His areas of scientific research include immunogenetics and molecular mechanisms of the aforementioned immune-mediated and inflammatory skin diseases. Professor Bachelez has received several scientific awards, including the Charles Grupper and Robert Degos awards, and the Sven Hellenström Lecture award. He is a member of several national and international scientific societies, including the European Academy of Dermatology and Venereology and the European Dermatology Forum (EDF). He is the former president of the French society for Dermatological Research and of the Group for Research on Psoriasis of the French Society for Dermatology. Internationally, he is the former President of the European Society for Dermatological Research (ESDR) and of the International Psoriasis Council (IPC). Professor Bachelez has published more than 310 manuscripts in peer-reviewed journals, among which more than 150 focusing on psoriasis, including the New England Journal of Medicine, Journal of Clinical Investigation, Journal of Experimental Medicine, the Lancet, Journal of Allergy and Clinical Immunology, and Arthritis and Rheumatism as leading author. Among Professor Bachelez' most prominent scientific achievements is the pioneering identification of gene defects of the IL36 pathway causing generalized pustular psoriasis, which led to the successful development of tailored therapies.



PAOLO AMERIO

Paolo Amerio, MD, PhD, is a Full Professor and Director of the Dermatology Clinic at G. d'Annunzio University in Chieti. His expertise lies in dermat immunology and photodermatology, and he has experience in autoimmune bullous diseases, dermato-rheumatologic conditions and vitiligo.

He is a reviewer for journals such as the British Journal of Dermatology, the International Journal of Dermatology and the International Journal of Immunopathology and Pharmacology. As well as presenting at congresses both nationally and internationally, he has co-authored over 170 peer-reviewed articles and participated in a clinical trial evaluating the safety and efficacy of baricitinib in combination with topical corticosteroids in adult patients.




LLUÍS PUIG SANZ

I am Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP) and Professor of Dermatology at the Universitat Autònoma de Barcelona (UAB) Medical School, Barcelona, Spain.

In the last 20 years my clinical research has focused on the treatment of psoriasis with biological agents, where I am considered a key opinion leader both nationally and internationally, having taught at numerous national and international conferences, workshops, and seminars. The results of my research have been published in numerous articles (h-index = 86; i10 index = 491) <https://www.ncbi.nlm.nih.gov/myncbi/1F145qcX7mdQs/bibliography/public/> and book chapters. I have participated, in most cases acting as principal investigator, in numerous clinical trials in psoriasis.


I am a member of the Spanish Academy of Dermatology and Venereology, founding member of several of its working groups, and past coordinator of the Spanish Psoriasis Group. I am also an aggregate member of the Spanish Society of Rheumatology and its GEAPSO Group for Research in Psoriatic Arthritis, and of several international societies, including the EADV, AAD, CILAD, ESDR, ASDP, ISDP, and GRAPPA.

I am or have been Board Member of the EADV (2013-2019), Co-chair of the Psoriasis Task Force of the EADV (2018-), scientific advisor to the Psoriasis International Network, President of the Psoriasis International Network and the Fondation René Touraine Scientific Board Executive Committee (2016-2020), Vicepresident of the Administration Council of the Fondation René Touraine (2018-2020), Member of the European Dermatology Forum (2017-), Councilor of the International Psoriasis Council (2012-), Board Member of the International Psoriasis Council (2018-), Member of the Education and Steering Committees (2020-2023) of GRAPPA, and Board Member at Large (Derm), GRAPPA (2024-)



RACHEL SOMMER

PD Dr. Rachel Sommer, MPH, is Head of the Psychodermatology at the Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf (UKE), Germany. Her research focuses on the interface between dermatology and mental health, with a particular emphasis on chronic inflammatory skin diseases, including psoriasis, vitiligo, and atopic dermatitis. She specializes in patient-centered dermatology, psychosocial outcomes, stigma, and the development and evaluation of evidence-based interventions to improve clinical care and quality of life. Dr. Sommer has authored more than 90 peer-reviewed publications and is actively involved in several international dermatology initiatives, including the EADV International Vitiligo Task Force. Her work has received multiple national and international awards and contributes to advancing the integration of psychodermatology into routine dermatological care. In 2021, she completed her habilitation (assistant professorship) in health services research at the Institute for Health Services Research in Dermatology and the Nursing Professions.



All Scientific Seminars International Foundation programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This independent educational program is made possible thanks to an independent educational grant received from Lilly.

**For registration
CLICK HERE**

